case report of a patient undergoing peritoneal dialysis with encapsulating peritoneal sclerosis superimposed with calciphylaxis

conclusions we suggest avoiding the use of tamoxifen for eps in patients with superimposed calciphylaxis. introduction encapsulating peritoneal sclerosis (eps) is a rare but devastating complication of peritoneal dialysis (pd). tamoxifen has been generally well-tolerated, even without randomized controlled trials. case presentation herein, we report a case of a patient undergoing 12 years of pd who developed eps and calciphylaxis simultaneously. we also provide a comprehensive discussion about the association between eps and calciphylaxis. moreover, although tamoxifen is used in eps due to its inhibition of fibroblast-transforming growth factor beta (tgfβ) production, it may worsen the calciphylaxis due to a hypercoagulable state.